{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:56Z","timestamp":1761896456783},"reference-count":103,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Outcomes in patients with follicular lymphoma (FL) have improved dramatically over the last decade. However, novel agents are greatly needed for those who exhibit treatment resistance, in order to minimize lifelong toxicity and to enable combinations that may allow us to achieve the elusive goal of cure. Biological advances have led to the discovery of a large number of potential therapeutic targets and the development of a plethora of novel agents designed to exploit these processes. Possible targets include tumor cell surface markers, key components of intracellular pathways and epigenetic mechanisms, and reactive cells of the microenvironment. Given the large number of candidate drugs and potential combinations, it will be crucial to prioritize evaluation based on sound preclinical and early clinical studies. Combinations that exploit driver mechanisms within tumor cells and target parallel pathways to minimize the development of drug resistance, as well as harness the potential of the immune system would seem most logical. In order to expedite progress, future studies will need to use innovative trial designs and employ surrogate end points. The development of validated prognostic tools to identify higher risk patients and reliable predictive markers to select subgroups most likely to benefit from targeted agents will be paramount. The potential for unexpected toxicity with novel combinations must be recognized, necessitating both short- and long-term vigilance. Finally, as a greater number of treatment options become available, optimal sequencing must be determined in order to both prolong life and maintain its quality.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.284","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"284-292","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Novel agents in follicular lymphoma: choosing the best target"],"prefix":"10.1182","volume":"2016","author":[{"given":"Laurie H.","family":"Sehn","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, and the University of British Columbia, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"15","key":"2019111703184414300_B1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703184414300_B2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111703184414300_B3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2019111703184414300_B4","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111703184414300_B5","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111703184414300_B6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703184414300_B7","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111703184414300_B8","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"key":"2019111703184414300_B9","article-title":"A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab-containing therapy (Homer): results of the interim analysis","author":"Maloney"},{"issue":"5","key":"2019111703184414300_B10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111703184414300_B11","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703184414300_B12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2010.037390","article-title":"Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin\u2019s lymphoma","volume":"96","author":"Negrea","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2019111703184414300_B13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13354","article-title":"The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"169","author":"Christian","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703184414300_B14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2014.911859","article-title":"Phase 1\/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity Fc\u03b3RIIIa patients with previously treated follicular lymphoma","volume":"56","author":"Ganjoo","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2019111703184414300_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1538.1538","article-title":"Ublituximab + TGR-1202 demonstrates activity and a favorable safety profile in relapsed\/refractory B-cell NHL and high-risk CLL: phase I results [abstract]","volume":"126","author":"Lunning","year":"2015","journal-title":"Blood"},{"issue":"suppl 5","key":"2019111703184414300_B16","article-title":"A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab [abstract]","volume":"32","author":"O\u2019Connor","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703184414300_B17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2019111703184414300_B18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111703184414300_B19","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111703184414300_B20","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn","year":"2012","journal-title":"Blood"},{"issue":"30","key":"2019111703184414300_B21","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS Study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111703184414300_B22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"2019111703184414300_B23","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703184414300_B24","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"2019111703184414300_B25","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"issue":"24","key":"2019111703184414300_B26","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111703184414300_B27","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703184414300_B28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111703184414300_B29","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111703184414300_B30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2013-07-512137","article-title":"A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia","volume":"123","author":"Byrd","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111703184414300_B31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.13099","article-title":"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(\u2122) therapeutic protein, for relapsed or refractory NHL patients","volume":"168","author":"Pagel","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111703184414300_B32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10637-014-0125-2","article-title":"Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR\u2122 therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients","volume":"32","author":"Gopal","year":"2014","journal-title":"Invest New Drugs"},{"issue":"23","key":"2019111703184414300_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2740.2740","article-title":"Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): initial results of a phase I first-in-man study in hematologic malignancies [abstract]","volume":"126","author":"Stephens","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111703184414300_B34","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111703184414300_B35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111703184414300_B36","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111703184414300_B37","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood-2013-10-492223","article-title":"Advances in the treatment of hematologic malignancies using immunoconjugates","volume":"123","author":"Palanca-Wessels","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111703184414300_B38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703184414300_B39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111703184414300_B40","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-15-2488","article-title":"Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed\/refractory CD22+ B-cell non-Hodgkin lymphoma","volume":"22","author":"Ogura","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111703184414300_B41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","article-title":"A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","volume":"174","author":"Goy","year":"2016","journal-title":"Br J Haematol"},{"issue":"20","key":"2019111703184414300_B42","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111703184414300_B43","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111703184414300_B44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111703184414300_B45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.13992","article-title":"A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"173","author":"Coiffier","year":"2016","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111703184414300_B46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4400.4400","article-title":"Final results of a phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) [abstract]","volume":"122","author":"Palanca-Wessels","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4457.4457","article-title":"Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]","volume":"124","author":"Morschhauser","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111703184414300_B48","article-title":"Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL) [abstract]","volume":"32","author":"Stathis","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019111703184414300_B49","article-title":"A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies [abstract]","volume-title":"J Clin Oncol","author":"Sawas","year":"2016"},{"issue":"12","key":"2019111703184414300_B50","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"2019111703184414300_B51","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111703184414300_B52","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111703184414300_B53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111703184414300_B54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703184414300_B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial [abstract]","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111703184414300_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.470.470","article-title":"Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study [abstract]","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703184414300_B57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703184414300_B58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2019111703184414300_B59","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111703184414300_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2744.2744","article-title":"Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy [abstract]","volume":"126","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.802.802","article-title":"A phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL [abstract]","volume":"124","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111703184414300_B62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3928.3928","article-title":"Combination trial of duvelisib (IPI-145) with bendamustine, rituximab, or bendamustine\/rituximab in patients with lymphoma or chronic lymphocytic leukemia [abstract]","volume":"126","author":"Flinn","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111703184414300_B63","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111703184414300_B64","article-title":"Phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in indolent non-Hodgkin\u2019s lymphoma (iNHL) [abstract]","volume":"126","author":"Sharman","year":"2015","journal-title":"Blood"},{"issue":"supp 5","key":"2019111703184414300_B65","article-title":"Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) [abstract]","volume":"32","author":"Barr","year":"2014","journal-title":"J Clin Oncol."},{"issue":"2","key":"2019111703184414300_B66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"2019111703184414300_B67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703184414300_B68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2019111703184414300_B69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111703184414300_B70","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019111703184414300_B71","article-title":"Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses [abstract]","volume":"32","author":"Davids","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111703184414300_B72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199 \/ GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111703184414300_B73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.255.255","article-title":"A dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma [abstract]","volume":"126","author":"de Vos","year":"2015","journal-title":"Blood"},{"issue":"5659","key":"2019111703184414300_B74","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"issue":"14","key":"2019111703184414300_B75","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J Med Chem"},{"key":"2019111703184414300_B76","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12756","article-title":"Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2 selective antagonist idasanutlin (RG7388)","author":"Herting","year":"2016","journal-title":"Eur J Haematol"},{"issue":"7360","key":"2019111703184414300_B77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"2019111703184414300_B78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"2019111703184414300_B79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"7337","key":"2019111703184414300_B80","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111703184414300_B81","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"B\u00f6d\u00f6r","year":"2011","journal-title":"Leukemia"},{"issue":"7427","key":"2019111703184414300_B82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"52","key":"2019111703184414300_B83","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2019111703184414300_B84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients [abstract]","volume":"126","author":"Ribrag","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B85","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111703184414300_B86","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111703184414300_B87","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111703184414300_B88","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703184414300_B89","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111703184414300_B90","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4458.4458","article-title":"A phase Ib study of obinutuzumab combined with lenalidomide for relapsed\/refractory follicular B-cell lymphoma [abstract]","volume":"124","author":"Morschhauser","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.248.248","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study [abstract]","volume":"122","author":"Tilly","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B92","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703184414300_B93","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3091.3091","article-title":"Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: Alliance A051201 and A051202 [abstract]","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111703184414300_B94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2019111703184414300_B95","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111703184414300_B96","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111703184414300_B97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111703184414300_B98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111703184414300_B99","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111703184414300_B100","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111703184414300_B101","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111703184414300_B102","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111703184414300_B103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2016-04-709477","article-title":"Speed bumps on the road to a chemotherapy-free world for lymphoma patients","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/284\/1251377\/hem088366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/284\/1251377\/hem088366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T18:15:51Z","timestamp":1601230551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/284\/21117\/Novel-agents-in-follicular-lymphoma-choosing-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.284","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}